HMG

Evidence in perspective

The named U.S. product label is the appropriate source for its approved use, contraindications and handling. MENOPUR: the FSH component had an elimination half-life of 11–13 hours during the multiple-dose phase after SC or IM administration in pituitary-suppressed healthy premenopausal women. This does not assign a common half-life to every component, population or formulation; the labeled administration route is SC. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.

Who was studied

The population specified by this product label; other indications and jurisdictions remain outside this check.

What the sources found

Follicle development as part of assisted reproductive treatment in selected women.

Regulatory scope

U.S. label record for BLA021663. This does not confer authorization on other products using the ingredient name.

What remains unknown

Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.

How it works

MENOPUR menotropins, 75 IU FSH and 75 IU LH activity per vial

Consult the product label for pharmacology. A mechanism does not extend its approved indications.

Approved product exists

Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.

Understanding the evidence

Reported adverse effects

• Ovarian hyperstimulation, thrombosis, torsion and multiple pregnancy require specialist monitoring.

Named U.S. presentation only; selected label sections.

Source · Warnings and precautions / boxed warning